Patent ID: 11896560
Assignee: BOTANIX PHARMACEUTICALS LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A treatment regime for use in the treatment of dermatitis and inflammatory skin conditions, said regime comprising the administration of:
between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabidiol, 85% w/w and 95% w/w of hexamethyldisiloxane, octamethyltrisiloxane or combinations thereof, and between 1% w/w and 10% w/w of a residual solvent that is less volatile than hexamethyldisiloxane, octamethyltrisiloxane or combinations thereof such that less than 5% of the residual solvent evaporates at skin temperature over 24 hours and wherein the residual solvent is selected from fatty acids, fatty acid alcohols, fatty alcohols, glycols or alkanes, or ethers of any of these, wherein the cannabidiol is dissolved in the liquid or gel composition, and the total daily dose applied to the skin is between 20 mg and 2000 mg cannabidiol.